Indoco Remedies Limited (NSE:INDOCO)
India
· Delayed Price · Currency is INR | Market Cap | 21.45B |
| Revenue (ttm) | 17.24B |
| Net Income (ttm) | -106.60M |
| Shares Out | 92.25M |
| EPS (ttm) | -1.25 |
| PE Ratio | n/a |
| Forward PE | 46.13 |
| Dividend | 1.50 (0.65%) |
| Ex-Dividend Date | Sep 19, 2024 |
| Volume | 48,613 |
| Average Volume | 63,232 |
| Open | 239.33 |
| Previous Close | 238.86 |
| Day's Range | 226.72 - 239.33 |
| 52-Week Range | 190.00 - 387.55 |
| Beta | 0.39 |
| RSI | 46.02 |
| Earnings Date | May 16, 2025 |
About Indoco Remedies
Indoco Remedies Limited manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally. It offers stomatological, gastrointestinal, respiratory, anti-infectives, vitamins/minerals/nutrients, ophthal/ontological, dermatology, urological, anti-diabetic, gynaecological, lifestyle management, pain/analgesic, and cardiac products. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; a... [Read more]
Financial Performance
In 2023, Indoco Remedies's revenue was 18.17 billion, an increase of 8.91% compared to the previous year's 16.69 billion. Earnings were 984.60 million, a decrease of -30.78%.
Financial StatementsNews
Indoco Remedies shares drop 6% after US FDA issues Form 483 For Hyderabad CRO unit
Indoco Remedies’ stock fell 6% after its clinical research division, AnaCipher, received a Form 483 from the United States Food and Drug Administration (USFDA). As of 9:18 AM, the shares were trading ...
Indoco’s AnaCipher receives one Form 483 after USFDA inspection
Indoco Remedies Limited (Indoco) proudly announces that its Clinical Research Organisation, AnaCipher, has successfully completed a comprehensive 5-day inspection by the USFDA. The inspection took pla...
Indoco Remedies receives relief as GST department drops proceedings on Rs 15.51 crore tax claim
Indoco Remedies Limited announced that the Goods and Services Tax (GST) Authority has officially dropped proceedings related to a ₹15.51 crore tax claim against the company. The decision was issued by...
Indoco Remedies Q3 FY25 Results: Revenue declines 6.2% YoY to Rs 410.55 crore; Net loss widens to Rs 28.40 crore
Indoco Remedies Limited released its financial results for the quarter ending December 31, 2024 (Q3 FY25), reporting a decline in revenue and a net loss due to increased expenses and operational chall...
Indoco Remedies shares plunge over 7% as Goa facility receives USFDA warning letter
Indoco Remedies’ shares fell sharply by 7.52% today following a significant setback, as the company’s Goa facility, contributing 65-70% of its revenue, received a warning letter from the USFDA. The wa...
Indoco Remedies receives USFDA warning letter for Goa facility
Indoco Remedies has received a warning letter from the USFDA for its Goa facility, following an inspection conducted from July 16-26, 2024. This follows the earlier notification on October 11, 2024, w...
Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK
Indoco Remedies witnessed a significant 8% jump in its stock price following the announcement of a strategic distribution partnership with Clarity Pharma, UK. This collaboration is set to launch appro...
Indoco Remedies partners with Clarity Pharma to strengthen UK presence
The partnership combines Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s extensive distribution network and market expertise.
Indoco Remedies shares down nearly 2% after USFDA classifies Goa facility as ‘Official Action Indicated’
Indoco Remedies saw its shares drop nearly 2% on Monday after receiving an update from the U.S. Food and Drug Administration (USFDA) regarding its Goa Plant-II & III facilities. The USFDA has classifi...
Indoco Remedies stock in focus following USFDA issues OAI classification
Indoco Remedies has received an update from the U.S. Food and Drug Administration (USFDA) regarding its Goa Plant-II & III facilities located in Verna Industrial Area, Goa, following an inspection con...
Indoco Remedies’ Goa Plant-II & III Retains OAI Status After USFDA Inspection
Indoco Remedies Limited announced that its Goa Plant-II & III retained the “Official Action Indicated” (OAI) status following a July 2024 inspection by the U.S. FDA. The facility had received OAI in M...
Indoco Remedies shares surge 3% after company gets USFDA approval for Generic Cetirizine Hydrochloride tablets
Indoco Remedies shares jumped 3% after the company received final approval from the USFDA for its generic version of Cetirizine Hydrochloride Tablets USP, 10 mg. This over-the-counter medication is a ...
Indoco Remedies secures USFDA approval for Generic Cetirizine Hydrochloride tablets
Indoco Remedies Limited has announced that it has received final approval from the USFDA for its generic version of Cetirizine Hydrochloride Tablets USP, 10 mg. This over-the-counter medication is a g...